Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine

Inclusion Criteria (For Infant Group): * Healthy full-term infant after birth, Apgar score ≥7. * Guardian signed informed consent. * Guardian can comply with the requirements of the clinical trial. * Without administering immunoglobulin during the following period. * Axillary temperature ≤37.0 ℃. Inclusion Criteria (For Other Age Groups): * More than 1 month old healthy people, without the history of hepatitis B infection. * Subjects or their guardians signed informed consent. * After questioning medical history, physical examination and being judged as healthy subject. * Without the history of hepatitis B vaccination. * Subjects or their guardians can comply with requirements of the clinical trail. * Without other prevention drugs or immunoglobulin administered within two weeks before the clinical trail or during the following period. * Axillary temperature ≤37.0 ℃. Exclusion Criteria (For Infant Group): * Apgar score of infant after birth \<7. * With nervous system damage after birth, or with the family history of mental illness, epilepsy or encephalopathy. * With immune system dysfunction. * With vitamin deficiency. * With acute febrile diseases, or infectious diseases. * With congenital malformations, developmental disorders or serious chronic illness. * With thrombocytopenia or other coagulation disorders. * Administered immunoglobulin during the period of the clinical trail, especially administered Hepatitis B immunoglobulin to the infant of Hepatitis B infected mother. * With endemic disease. * Participate another clinical trial during the period of the clinical trail. * Any circumstance that may affect clinical trail evaluation. Exclusion Criteria (For Other Age Groups): * With allergies, seizures, epilepsy, encephalopathy or with family history of mental illness. * Allergic to any component of the study vaccine. * With immune system dysfunction. * Hepatitis B infected people. * Anti-HBs was positive screened by ELISA kit. * Either anti-HBs ≥10mIU/ml or HBsAg was positive screened by Radioimmunoassay method. * With acute febrile diseases or infectious diseases. * With congenital malformations, developmental disorders or serious chronic illness. * With thrombocytopenia or other coagulation disorders. * With the history of severe allergic reactions. * Administered other prevention drugs or immunoglobulin within two weeks before the clinical trail or during the following period. * With any acute illness that requires antibiotics or anti-viral treatment within 7 days before the clinical trail. * With vitamin deficiency. * With the history of febrile convulsion. * Axillary temperature ≥38.0 ℃ within 3 days before the clinical trail. * Participate another clinical trial during the period of the clinical trail. * Pregnant woman. * Any circumstance that may affect clinical trail evaluation.